JP2018531017A - 生産性向上のためのrna関連酵素の修飾 - Google Patents
生産性向上のためのrna関連酵素の修飾 Download PDFInfo
- Publication number
- JP2018531017A JP2018531017A JP2018519481A JP2018519481A JP2018531017A JP 2018531017 A JP2018531017 A JP 2018531017A JP 2018519481 A JP2018519481 A JP 2018519481A JP 2018519481 A JP2018519481 A JP 2018519481A JP 2018531017 A JP2018531017 A JP 2018531017A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sumo
- seq
- guanylyltransferase
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/0705—Nucleotidyltransferases (2.7.7) mRNA guanylyltransferase (2.7.7.50)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
【選択図】なし
Description
本出願は、2015年10月14日に出願された米国仮出願第62/241,350号に対する優先権を主張し、その開示は、参照により本明細書に援用される。
本明細書は、配列表(「SL_SHR−1187WO」という名称のテキスト(.txt)ファイルとして2016年10月14日に電子的に提出されたもの)を参照する。該テキストファイルは、2016年10月14日に作成されたものであり、サイズは28,402バイトである。配列表の全内容が、参照により本明細書に援用される。
本発明をより容易に理解するために、特定の用語を最初に定義する。以下の用語及び他の用語のさらなる定義は、本明細書全体を通して記載される。
SUMO−グアニリルトランスフェラーゼ融合タンパク質
低分子ユビキチン様修飾因子(SUMO)
表1.低分子ユビキチン様修飾因子
グアニリルトランスフェラーゼ(GT)
表2.グアニリルトランスフェラーゼ
SUMO−GT融合
表3.SUMO−GT融合
SUMO−GT融合タンパク質の産生
宿主細胞
発現ベクター
培養培地及び条件
発現SUMO−GT融合タンパク質の精製
溶解度
mRNAキャッピングにおけるSUMO−GT融合の使用
キャップされたmRNAの生成
キャッピング効率
グアニリルトランスフェラーゼ(GT)ヘテロ二量体の大サブユニット部分と共有結合し、かつ共発現する、低分子ユビキチン様修飾因子(SUMO)タグを組み込む新規な構築物を合成した。
低分子ユビキチン様修飾因子(SUMO)DNA:
GAAGAGAAACCGAAAGAGGGCGTTAAGACCGAGAATGACCACATTAACCTGAAGGTCGCTGGTCAAGATGGCAGCGTGGTGCAGTTTAAGATCAAGCGTCACACGCCGTTGAGCAAGCTGATGAAGGCTTACTGCGAGCGTCAGGGTCTGAGCATGCGTCAGATCCGCTTTCGTTTCGATGGCCAGCCGATCAATGAGACTGACACCCCAGCGCAACTGG(配列番号1)
グアニリルトランスフェラーゼ(GT)大サブユニットDNA:
AGATGGAAGATGAAGATACCATCGACGTCTTTCAGCAACAGACCGGTGGTATGGATGCTAACGTCGTTAGCAGCAGCACCATTGCGACTTACATTGATGCACTGGCCAAAAACGCATCTGAGCTTGAGCAGCGCAGCACCGCCTACGAGATCAATAACGAATTGGAGCTGGTTTTCATTAAACCGCCGCTGATCACGCTGACGAACGTCGTGAACATTAGCACGATTCAAGAGAGCTTTATTCGTTTCACCGTTACCAATAAAGAAGGCGTGAAGATCCGTACCAAGATTCCGCTGAGCAAAGTGCATGGTCTGGACGTGAAAAATGTGCAGCTGGTTGATGCGATCGATAACATCGTGTGGGAGAAGAAATCTTTGGTCACGGAAAATCGTCTGCACAAGGAATGTCTGCTGCGTCTGTCAACCGAAGAACGCCACATCTTCCTGGACTACAAGAAGTATGGTTCCAGCATCCGTCTGGAACTGGTGAACCTGATTCAGGCAAAGACCAAGAACTTCACCATTGACTTCAAACTGAAGTATTTCCTGGGCTCTGGTGCACAGAGCAAATCCAGCTTGTTGCACGCGATTAACCATCCGAAGAGCCGTCCGAATACGAGCCTGGAGATCGAATTCACGCCGCGTGATAACGAAACCGTTCCGTACGATGAGCTGATTAAAGAACTGACGACGTTGAGCCGCCACATCTTTATGGCCAGCCCGGAAAACGTGATCCTTAGCCCGCCTATCAATGCGCCGATTAAAACCTTTATGTTACCGAAACAAGACATTGTGGGTCTGGACCTGGAAAACCTGTACGCGGTCACCAAAACGGACGGCATTCCGATCACGATTCGTGTTACCAGCAATGGTCTGTACTGCTATTTCACTCATTTGGGCTATATCATTCGTTATCCGGTGAAACGCATCATTGATTCTGAGGTTGTCGTTTTCGGCGAAGCAGTCAAGGACAAGAATTGGACTGTGTACCTGATCAAATTGATTGAACCGGTTAACGCCATCAATGACCGCCTGGAAGAGTCGAAATATGTTGAAAGCAAACTGGTGGATATTTGTGATCGTATCGTGTTCAAGAGCAAGAAATATGAAGGCCCGTTCACCACGACCAGCGAAGTTGTTGACATGCTGAGCACCTATCTGCCGAAACAACCTGAGGGTGTGATTCTGTTTTACTCCAAGGGTCCGAAGAGCAACATTGATTTCAAAATCAAGAAAGAGAATACCATTGATCAGACCGCCAACGTTGTGTTCCGCTATATGTCCAGCGAGCCTATCATTTTCGGTGAGTCGAGCATCTTTGTTGAATACAAAAAGTTTAGCAACGATAAGGGTTTTCCGAAAGAATACGGTTCCGGTAAGATTGTGTTGTACAACGGCGTCAATTATCTGAACAACATCTACTGTCTGGAGTACATCAATACCCATAACGAAGTTGGCATTAAGTCTGTTGTCGTCCCGATCAAATTCATCGCGGAGTTCCTGGTTAACGGTGAGATTCTGAAGCCGCGTATTGATAAAACTATGAAATACATTAACTCCGAAGATTACTACGGTAATCAGCATAACATCATCGTCGAGCACTTGCGTGATCAAAGCATTAAGATCGGTGACATCTTTAACGAAGATAAGCTGAGCGATGTAGGCCACCAGTATGCGAACAATGACAAATTTCGCCTGAATCCGGAAGTCAGCTACTTTACGAATAAGCGCACCCGTGGTCCACTGGGTATCCTGAGCAATTATGTTAAAACCCTGTTGATTTCCATGTACTGCTCCAAAACGTTCCTGGACGACAGCAACAAGCGCAAAGTTCTGGCGATCGACTTCGGTAATGGTGCCGATCTGGAGAAGTACTTTTATGGTGAGATCGCATTGCTGGTTGCTACCGACCCGGATGCAGATGCGATCGCCCGTGGCAACGAGCGTTACAATAAGCTGAATAGCGGTATCAAGACCAAATACTACAAATTCGACTATATTCAAGAGACGATCCGCTCGGACACCTTTGTATCCAGCGTGCGTGAGGTGTTTTACTTCGGTAAATTCAACATCATTGACTGGCAATTCGCCATTCACTATAGCTTTCACCCACGCCACTATGCGACGGTCATGAACAACCTGTCTGAGCTGACCGCGAGCGGCGGTAAAGTTCTGATCACCACGATGGACGGTGACAAGCTGTCTAAACTGACCGACAAAAAGACCTTCATTATTCACAAAAATCTCCCGTCGAGCGAGAATTACATGTCCGTCGAAAAGATTGCGGACGACCGTATTGTTGTCTACAACCCGAGCACTATGTCGACCCCAATGACCGAGTATATCATCAAAAAGAATGACATTGTGCGTGTCTTTAATGAATACGGTTTTGTGCTGGTCGACAACGTCGATTTTGCGACCATCATCGAGAGAAGCAAGAAATTCATTAATGGCGCTTCTACGATGGAAGATCGCCCGAGCACGCGTAACTTCTTTGAGCTGAATCGTGGCGCGATTAAGTGCGAGGGCCTGGACGTCGAGGATCTGCTGTCGTATTACGTGGTTTATGTGTTTAGCAAACGTTAATGA(配列番号2)
グアニリルトランスフェラーゼ(GT)小サブユニットDNA:
ATGGACGAAATTGTCAAGAATATCCGTGAAGGTACCCACGTTTTACTGCCATTCTACGAGACGCTGCCGGAACTGAACCTGAGCCTGGGTAAAAGCCCTCTGCCGAGCCTGGAGTATGGTGCGAACTATTTTCTGCAGATTTCCCGTGTAAACGATTTGAACCGCATGCCGACGGACATGCTGAAACTGTTCACCCACGACATCATGCTGCCGGAATCTGATCTGGATAAAGTTTACGAGATCTTGAAAATCAATTCAGTGAAGTACTATGGCCGTAGCACCAAGGCCGATGCGGTGGTCGCAGACCTGAGCGCGCGTAACAAACTGTTTAAACGTGAACGTGACGCAATTAAGAGCAATAACCATCTGACCGAGAACAATTTGTACATCAGCGACTACAAGATGTTGACTTTTGACGTGTTTCGTCCGCTGTTCGACTTTGTTAATGAGAAATACTGCATTATCAAGCTGCCGACGTTGTTTGGTCGCGGCGTCATTGATACGATGCGCATTTACTGCTCTCTCTTCAAGAATGTGCGCCTGCTGAAGTGTGTCTCCGACAGCTGGCTGAAAGATAGCGCTATTATGGTTGCGAGCGACGTGTGTAAAAAGAACCTGGATCTGTTCATGAGCCACGTGAAGAGCGTTACCAAAAGCAGCAGCTGGAAAGACGTTAACAGCGTCCAGTTCTCCATTCTGAATAACCCGGTCGATACCGAGTTTATCAACAAGTTCCTTGAATTCAGCAATCGCGTTTATGAGGCCCTGTATTACGTTCATAGCCTGCTGTATAGCTCCATGACCTCTGATAGCAAATCGATCGAGAATAAACACCAACGTCGTCTGGTGAAACTGCTGCTGTAATGA(配列番号3)
Hisタグ及びリンカーを備えたSUMO−GT大サブユニットDNA構築物:
ATGGGCCATCATCATCACCATCACGGCAGCCTGCAAGAAGAGAAACCGAAAGAGGGCGTTAAGACCGAGAATGACCACATTAACCTGAAGGTCGCTGGTCAAGATGGCAGCGTGGTGCAGTTTAAGATCAAGCGTCACACGCCGTTGAGCAAGCTGATGAAGGCTTACTGCGAGCGTCAGGGTCTGAGCATGCGTCAGATCCGCTTTCGTTTCGATGGCCAGCCGATCAATGAGACTGACACCCCAGCGCAACTGGAGATGGAAGATGAAGATACCATCGACGTCTTTCAGCAACAGACCGGTGGTATGGATGCTAACGTCGTTAGCAGCAGCACCATTGCGACTTACATTGATGCACTGGCCAAAAACGCATCTGAGCTTGAGCAGCGCAGCACCGCCTACGAGATCAATAACGAATTGGAGCTGGTTTTCATTAAACCGCCGCTGATCACGCTGACGAACGTCGTGAACATTAGCACGATTCAAGAGAGCTTTATTCGTTTCACCGTTACCAATAAAGAAGGCGTGAAGATCCGTACCAAGATTCCGCTGAGCAAAGTGCATGGTCTGGACGTGAAAAATGTGCAGCTGGTTGATGCGATCGATAACATCGTGTGGGAGAAGAAATCTTTGGTCACGGAAAATCGTCTGCACAAGGAATGTCTGCTGCGTCTGTCAACCGAAGAACGCCACATCTTCCTGGACTACAAGAAGTATGGTTCCAGCATCCGTCTGGAACTGGTGAACCTGATTCAGGCAAAGACCAAGAACTTCACCATTGACTTCAAACTGAAGTATTTCCTGGGCTCTGGTGCACAGAGCAAATCCAGCTTGTTGCACGCGATTAACCATCCGAAGAGCCGTCCGAATACGAGCCTGGAGATCGAATTCACGCCGCGTGATAACGAAACCGTTCCGTACGATGAGCTGATTAAAGAACTGACGACGTTGAGCCGCCACATCTTTATGGCCAGCCCGGAAAACGTGATCCTTAGCCCGCCTATCAATGCGCCGATTAAAACCTTTATGTTACCGAAACAAGACATTGTGGGTCTGGACCTGGAAAACCTGTACGCGGTCACCAAAACGGACGGCATTCCGATCACGATTCGTGTTACCAGCAATGGTCTGTACTGCTATTTCACTCATTTGGGCTATATCATTCGTTATCCGGTGAAACGCATCATTGATTCTGAGGTTGTCGTTTTCGGCGAAGCAGTCAAGGACAAGAATTGGACTGTGTACCTGATCAAATTGATTGAACCGGTTAACGCCATCAATGACCGCCTGGAAGAGTCGAAATATGTTGAAAGCAAACTGGTGGATATTTGTGATCGTATCGTGTTCAAGAGCAAGAAATATGAAGGCCCGTTCACCACGACCAGCGAAGTTGTTGACATGCTGAGCACCTATCTGCCGAAACAACCTGAGGGTGTGATTCTGTTTTACTCCAAGGGTCCGAAGAGCAACATTGATTTCAAAATCAAGAAAGAGAATACCATTGATCAGACCGCCAACGTTGTGTTCCGCTATATGTCCAGCGAGCCTATCATTTTCGGTGAGTCGAGCATCTTTGTTGAATACAAAAAGTTTAGCAACGATAAGGGTTTTCCGAAAGAATACGGTTCCGGTAAGATTGTGTTGTACAACGGCGTCAATTATCTGAACAACATCTACTGTCTGGAGTACATCAATACCCATAACGAAGTTGGCATTAAGTCTGTTGTCGTCCCGATCAAATTCATCGCGGAGTTCCTGGTTAACGGTGAGATTCTGAAGCCGCGTATTGATAAAACTATGAAATACATTAACTCCGAAGATTACTACGGTAATCAGCATAACATCATCGTCGAGCACTTGCGTGATCAAAGCATTAAGATCGGTGACATCTTTAACGAAGATAAGCTGAGCGATGTAGGCCACCAGTATGCGAACAATGACAAATTTCGCCTGAATCCGGAAGTCAGCTACTTTACGAATAAGCGCACCCGTGGTCCACTGGGTATCCTGAGCAATTATGTTAAAACCCTGTTGATTTCCATGTACTGCTCCAAAACGTTCCTGGACGACAGCAACAAGCGCAAAGTTCTGGCGATCGACTTCGGTAATGGTGCCGATCTGGAGAAGTACTTTTATGGTGAGATCGCATTGCTGGTTGCTACCGACCCGGATGCAGATGCGATCGCCCGTGGCAACGAGCGTTACAATAAGCTGAATAGCGGTATCAAGACCAAATACTACAAATTCGACTATATTCAAGAGACGATCCGCTCGGACACCTTTGTATCCAGCGTGCGTGAGGTGTTTTACTTCGGTAAATTCAACATCATTGACTGGCAATTCGCCATTCACTATAGCTTTCACCCACGCCACTATGCGACGGTCATGAACAACCTGTCTGAGCTGACCGCGAGCGGCGGTAAAGTTCTGATCACCACGATGGACGGTGACAAGCTGTCTAAACTGACCGACAAAAAGACCTTCATTATTCACAAAAATCTCCCGTCGAGCGAGAATTACATGTCCGTCGAAAAGATTGCGGACGACCGTATTGTTGTCTACAACCCGAGCACTATGTCGACCCCAATGACCGAGTATATCATCAAAAAGAATGACATTGTGCGTGTCTTTAATGAATACGGTTTTGTGCTGGTCGACAACGTCGATTTTGCGACCATCATCGAGAGAAGCAAGAAATTCATTAATGGCGCTTCTACGATGGAAGATCGCCCGAGCACGCGTAACTTCTTTGAGCTGAATCGTGGCGCGATTAAGTGCGAGGGCCTGGACGTCGAGGATCTGCTGTCGTATTACGTGGTTTATGTGTTTAGCAAACGTTAATGA(配列番号4)
低分子ユビキチン様修飾因子(SUMO)タンパク質:
EEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG(配列番号5)
グアニリルトランスフェラーゼ(GT)大サブユニットタンパク質:
MDANVVSSSTIATYIDALAKNASELEQRSTAYEINNELELVFIKPPLITLTNVVNISTIQESFIRFTVTNKEGVKIRTKIPLSKVHGLDVKNVQLVDAIDNIVWEKKSLVTENRLHKECLLRLSTEERHIFLDYKKYGSSIRLELVNLIQAKTKNFTIDFKLKYFLGSGAQSKSSLLHAINHPKSRPNTSLEIEFTPRDNETVPYDELIKELTTLSRHIFMASPENVILSPPINAPIKTFMLPKQDIVGLDLENLYAVTKTDGIPITIRVTSNGLYCYFTHLGYIIRYPVKRIIDSEVVVFGEAVKDKNWTVYLIKLIEPVNAINDRLEESKYVESKLVDICDRIVFKSKKYEGPFTTTSEVVDMLSTYLPKQPEGVILFYSKGPKSNIDFKIKKENTIDQTANVVFRYMSSEPIIFGESSIFVEYKKFSNDKGFPKEYGSGKIVLYNGVNYLNNIYCLEYINTHNEVGIKSVVVPIKFIAEFLVNGEILKPRIDKTMKYINSEDYYGNQHNIIVEHLRDQSIKIGDIFNEDKLSDVGHQYANNDKFRLNPEVSYFTNKRTRGPLGILSNYVKTLLISMYCSKTFLDDSNKRKVLAIDFGNGADLEKYFYGEIALLVATDPDADAIARGNERYNKLNSGIKTKYYKFDYIQETIRSDTFVSSVREVFYFGKFNIIDWQFAIHYSFHPRHYATVMNNLSELTASGGKVLITTMDGDKLSKLTDKKTFIIHKNLPSSENYMSVEKIADDRIVVYNPSTMSTPMTEYIIKKNDIVRVFNEYGFVLVDNVDFATIIERSKKFINGASTMEDRPSTRNFFELNRGAIKCEGLDVEDLLSYYVVYVFSKR(配列番号6)
グアニリルトランスフェラーゼ(GT)小サブユニットタンパク質:
MDEIVKNIREGTHVLLPFYETLPELNLSLGKSPLPSLEYGANYFLQISRVNDLNRMPTDMLKLFTHDIMLPESDLDKVYEILKINSVKYYGRSTKADAVVADLSARNKLFKRERDAIKSNNHLTENNLYISDYKMLTFDVFRPLFDFVNEKYCIIKLPTLFGRGVIDTMRIYCSLFKNVRLLKCVSDSWLKDSAIMVASDVCKKNLDLFMSHVKSVTKSSSWKDVNSVQFSILNNPVDTEFINKFLEFSNRVYEALYYVHSLLYSSMTSDSKSIENKHQRRLVKLLL(配列番号7)
Hisタグ及びリンカーを備えたSUMO−GT大サブユニットタンパク質:
MGHHHHHHGSLQEEKPKEGVKTENDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGGMDANVVSSSTIATYIDALAKNASELEQRSTAYEINNELELVFIKPPLITLTNVVNISTIQESFIRFTVTNKEGVKIRTKIPLSKVHGLDVKNVQLVDAIDNIVWEKKSLVTENRLHKECLLRLSTEERHIFLDYKKYGSSIRLELVNLIQAKTKNFTIDFKLKYFLGSGAQSKSSLLHAINHPKSRPNTSLEIEFTPRDNETVPYDELIKELTTLSRHIFMASPENVILSPPINAPIKTFMLPKQDIVGLDLENLYAVTKTDGIPITIRVTSNGLYCYFTHLGYIIRYPVKRIIDSEVVVFGEAVKDKNWTVYLIKLIEPVNAINDRLEESKYVESKLVDICDRIVFKSKKYEGPFTTTSEVVDMLSTYLPKQPEGVILFYSKGPKSNIDFKIKKENTIDQTANVVFRYMSSEPIIFGESSIFVEYKKFSNDKGFPKEYGSGKIVLYNGVNYLNNIYCLEYINTHNEVGIKSVVVPIKFIAEFLVNGEILKPRIDKTMKYINSEDYYGNQHNIIVEHLRDQSIKIGDIFNEDKLSDVGHQYANNDKFRLNPEVSYFTNKRTRGPLGILSNYVKTLLISMYCSKTFLDDSNKRKVLAIDFGNGADLEKYFYGEIALLVATDPDADAIARGNERYNKLNSGIKTKYYKFDYIQETIRSDTFVSSVREVFYFGKFNIIDWQFAIHYSFHPRHYATVMNNLSELTASGGKVLITTMDGDKLSKLTDKKTFIIHKNLPSSENYMSVEKIADDRIVVYNPSTMSTPMTEYIIKKNDIVRVFNEYGFVLVDNVDFATIIERSKKFINGASTMEDRPSTRNFFELNRGAIKCEGLDVEDLLSYYVVYVFSKR(配列番号8)
実施例2:SUMO−GTタンパク質の生成
振盪フラスコ
発酵
等価物
Claims (29)
- キャップされたRNAまたはRNA類似体オリゴヌクレオチドを生成する方法であって、融合タンパク質により、グアニリル分子を、前記RNAまたはRNA類似体オリゴヌクレオチドの5’末端に導入し、かつメチル化する工程が促進される、前記方法。
- 前記融合タンパク質が、グアニリルトランスフェラーゼと低分子ユビキチン様(SUMO)タンパク質とを含む、請求項1に記載の方法。
- 前記グアニリルトランスフェラーゼが、配列番号6と配列番号7とを含み、前記SUMOタンパク質が、配列番号5を含む、請求項2に記載の方法。
- 前記融合タンパク質が、配列番号8と配列番号7とを含む、請求項2に記載の方法。
- 前記融合タンパク質が、野生型グアニリルトランスフェラーゼタンパク質と比較して同等のホスファターゼ活性、グアニリルトランスフェラーゼ活性、及びメチル化活性を有する、請求項1に記載の方法。
- グアニリルトランスフェラーゼと低分子ユビキチン様(SUMO)タンパク質とを含む、融合タンパク質。
- 前記グアニリルトランスフェラーゼが、配列番号6と配列番号7とを含み、前記SUMOタンパク質が、配列番号5を含む、請求項6に記載の融合タンパク質。
- 前記グアニリルトランスフェラーゼが、大サブユニットと小サブユニットとを含む、請求項6に記載の融合タンパク質。
- 前記SUMOタンパク質が、前記大サブユニットと共有結合し、かつ共発現する、請求項8に記載の融合タンパク質。
- 前記融合タンパク質が、野生型グアニリルトランスフェラーゼタンパク質と比較して同等のホスファターゼ活性、グアニリルトランスフェラーゼ活性、及びメチル化活性を有する、請求項6に記載の融合タンパク質。
- グアニリルトランスフェラーゼタンパク質と低分子ユビキチン様(SUMO)タンパク質とを含む融合タンパク質をコードするベクター。
- 前記ベクターが、配列番号1と配列番号2とを含む、請求項11に記載のベクター。
- 前記ベクターが、配列番号1、配列番号2、及び配列番号3を含む、請求項11に記載のベクター。
- 前記ベクターが、配列番号4と配列番号3とを含む、請求項11に記載のベクター。
- グアニリルトランスフェラーゼを発酵により生成する方法であって、a)発酵培地で、配列番号6及び配列番号7と少なくとも90%同一のアミノ酸配列を有するグアニリルトランスフェラーゼをコードする核酸配列を備えた、少なくとも1つの組換え核酸分子で形質転換された微生物を培養することと;b)前記培養する工程から生成された生成物を採取することと、を含む、前記方法。
- 前記グアニリルトランスフェラーゼが、グアニリルトランスフェラーゼ融合タンパク質を含む、請求項15に記載の方法。
- 前記グアニリルトランスフェラーゼ融合タンパク質が、野生型グアニリルトランスフェラーゼタンパク質と比較して同等のホスファターゼ活性、グアニリルトランスフェラーゼ活性、及びメチル化活性を有する、請求項16に記載の方法。
- 前記グアニリルトランスフェラーゼ融合タンパク質が、低分子ユビキチン様(SUMO)タンパク質を含む、請求項16に記載の方法。
- 前記グアニリルトランスフェラーゼ融合タンパク質が、配列番号8を含む、請求項18に記載の方法。
- 前記SUMOタンパク質が、グアニリルトランスフェラーゼに共有結合で結合している、請求項18に記載の方法。
- 前記共有結合が、前記SUMOタンパク質と前記グアニリルトランスフェラーゼの大サブユニットとの間にある、請求項20に記載の方法。
- 前記発酵培地が、Terrific Broth、Cinnabar、2×YT、及びLBからなる群から選択される、請求項15に記載の方法。
- 前記微生物が細菌である、請求項15に記載の方法。
- 前記グアニリルトランスフェラーゼをコードする前記核酸配列が、配列番号2及び配列番号3と少なくとも90%同一である、請求項15に記載の方法。
- 前記組換え核酸分子が、低分子ユビキチン様(SUMO)タンパク質をコードする核酸配列をさらに含む、請求項15に記載の方法。
- 低分子ユビキチン様(SUMO)タンパク質をコードする前記核酸配列が、配列番号1と少なくとも90%同一である、請求項25に記載の方法。
- 前記生成物がグアニリルトランスフェラーゼである、請求項15に記載の方法。
- 前記生成物が、グアニリルトランスフェラーゼ融合タンパク質を含むグアニリルトランスフェラーゼである、請求項27に記載の方法。
- 前記グアニリルトランスフェラーゼ融合タンパク質が、低分子ユビキチン様(SUMO)タンパク質をさらに含む、請求項28に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021108662A JP7119181B6 (ja) | 2015-10-14 | 2021-06-30 | 生産性向上のためのrna関連酵素の修飾 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241350P | 2015-10-14 | 2015-10-14 | |
US62/241,350 | 2015-10-14 | ||
PCT/US2016/057044 WO2017066573A1 (en) | 2015-10-14 | 2016-10-14 | Modification of rna-related enzymes for enhanced production |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021108662A Division JP7119181B6 (ja) | 2015-10-14 | 2021-06-30 | 生産性向上のためのrna関連酵素の修飾 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018531017A true JP2018531017A (ja) | 2018-10-25 |
JP2018531017A6 JP2018531017A6 (ja) | 2018-12-13 |
JP6997704B2 JP6997704B2 (ja) | 2022-02-04 |
Family
ID=57288485
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018519481A Active JP6997704B2 (ja) | 2015-10-14 | 2016-10-14 | 生産性向上のためのrna関連酵素の修飾 |
JP2021108662A Active JP7119181B6 (ja) | 2015-10-14 | 2021-06-30 | 生産性向上のためのrna関連酵素の修飾 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021108662A Active JP7119181B6 (ja) | 2015-10-14 | 2021-06-30 | 生産性向上のためのrna関連酵素の修飾 |
Country Status (9)
Country | Link |
---|---|
US (4) | US10144942B2 (ja) |
EP (2) | EP3878955A1 (ja) |
JP (2) | JP6997704B2 (ja) |
CN (2) | CN114686548A (ja) |
AU (1) | AU2016338559B2 (ja) |
CA (1) | CA3001852A1 (ja) |
ES (1) | ES2862412T3 (ja) |
MA (1) | MA56219A (ja) |
WO (1) | WO2017066573A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103748078B (zh) | 2011-06-08 | 2016-11-09 | 夏尔人类遗传性治疗公司 | 可裂解脂质 |
CN111212905A (zh) | 2017-08-18 | 2020-05-29 | 摩登纳特斯有限公司 | Rna聚合酶变体 |
JP2022521094A (ja) | 2019-02-20 | 2022-04-05 | モデルナティエックス インコーポレイテッド | 共転写キャッピング用rnaポリメラーゼバリアント |
CN112714795A (zh) * | 2019-08-23 | 2021-04-27 | 新英格兰生物实验室公司 | 酶促rna加帽方法 |
CN116286562A (zh) * | 2021-12-10 | 2023-06-23 | 虹摹生物科技(上海)有限公司 | 一种基因工程菌及其制备方法和应用 |
CN114369587B (zh) * | 2021-12-25 | 2024-03-15 | 苏州瀚源新酶生物科技有限公司 | 牛痘病毒加帽酶突变体、重组载体、重组工程菌及其应用 |
CN114480346B (zh) * | 2022-02-18 | 2023-07-21 | 嘉兴维亚生物科技有限公司 | 一种dna水解酶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004532033A (ja) * | 2001-05-04 | 2004-10-21 | コーネル リサーチ ファンデイション インコーポレイテッド | 発現し難いタンパク質用の迅速に開裂可能なsumo融合タンパク質発現系 |
JP2010514451A (ja) * | 2006-12-29 | 2010-05-06 | ライフセンサーズ、インク. | タンパク質の発現増強および精製の方法および組成 |
WO2014028429A2 (en) * | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256555A (en) | 1991-12-20 | 1993-10-26 | Ambion, Inc. | Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
ES2231819T3 (es) | 1995-06-07 | 2005-05-16 | Inex Pharmaceuticals Corp | Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes. |
US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
EP1482031B1 (en) | 1996-08-30 | 2015-10-28 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
DK1519714T3 (da) | 2002-06-28 | 2011-01-31 | Protiva Biotherapeutics Inc | Fremgangsmåde og apparat til fremstilling af liposomer |
US7655413B2 (en) * | 2003-06-26 | 2010-02-02 | Lifesensors, Inc. | Methods and compositions for enhanced protein expression and purification |
EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
EP1781593B1 (en) | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
WO2006073976A2 (en) * | 2004-12-30 | 2006-07-13 | Lifesensors, Inc. | Compositions, methods, and kits for enhancing protein expression, solubility and isolation |
CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
US20090247608A1 (en) | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
WO2009082817A1 (en) | 2007-12-27 | 2009-07-09 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
WO2009088891A1 (en) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
JP5788312B2 (ja) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達 |
PL2279254T3 (pl) | 2008-04-15 | 2017-11-30 | Protiva Biotherapeutics Inc. | Nowe preparaty lipidowe do dostarczania kwasów nukleinowych |
EP2350043B9 (en) | 2008-10-09 | 2014-08-20 | TEKMIRA Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
KR102264822B1 (ko) | 2008-11-10 | 2021-06-14 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
CA2750561C (en) | 2009-01-26 | 2017-10-10 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein c-iii expression |
CA3042927C (en) | 2009-05-05 | 2022-05-17 | Arbutus Biopharma Corporation | Lipid compositions for the delivery of therapeutic agents |
EA028860B1 (ru) | 2009-06-10 | 2018-01-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
WO2011000108A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein b |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
US8716464B2 (en) | 2009-07-20 | 2014-05-06 | Thomas W. Geisbert | Compositions and methods for silencing Ebola virus gene expression |
RS58405B1 (sr) | 2009-12-01 | 2019-04-30 | Translate Bio Inc | Stereoidni derivati za isporuku irnk u humanim genetskim oboljenjima |
AU2010330814B2 (en) | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
EP2569276B1 (en) | 2010-05-12 | 2021-02-24 | Arbutus Biopharma Corporation | Novel cationic lipids and methods of use thereof |
US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HUE058896T2 (hu) | 2010-10-01 | 2022-09-28 | Modernatx Inc | N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai |
US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
AU2012255913A1 (en) | 2011-05-17 | 2013-11-21 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof for non-human vertebrates |
RS59037B1 (sr) | 2011-06-08 | 2019-08-30 | Translate Bio Inc | Kompozicije lipidnih nanočestica i postupci za isporuku irnk |
EP3384938A1 (en) | 2011-09-12 | 2018-10-10 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
JP2014530602A (ja) | 2011-10-05 | 2014-11-20 | プロティバ バイオセラピューティクス インコーポレイテッド | アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法 |
US20140343129A1 (en) | 2011-12-14 | 2014-11-20 | Moderna Therapeutics, Inc. | Modified nucleic acids, and acute care uses thereof |
EP2791364A4 (en) | 2011-12-14 | 2015-11-11 | Moderna Therapeutics Inc | METHODS OF RESPONSE TO A BIOLOGICAL THREAT |
EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
US20130165504A1 (en) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
US20140371302A1 (en) | 2011-12-29 | 2014-12-18 | Modema Therapeutics, Inc. | Modified mrnas encoding cell-penetrating polypeptides |
WO2013126803A1 (en) | 2012-02-24 | 2013-08-29 | Protiva Biotherapeutics Inc. | Trialkyl cationic lipids and methods of use thereof |
US20140275229A1 (en) | 2012-04-02 | 2014-09-18 | Moderna Therapeutics, Inc. | Modified polynucleotides encoding udp glucuronosyltransferase 1 family, polypeptide a1 |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
WO2013151666A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243951A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
US20150050354A1 (en) | 2012-04-02 | 2015-02-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for the treatment of otic diseases and conditions |
US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
ES2968649T3 (es) | 2012-12-07 | 2024-05-13 | Translate Bio Inc | Nanopartículas lipídicas para la administración de ARNm en los pulmones |
US20150315541A1 (en) | 2012-12-13 | 2015-11-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
EP3434774A1 (en) | 2013-01-17 | 2019-01-30 | ModernaTX, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
WO2014158795A1 (en) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnosis and treatment of fibrosis |
WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2971098B1 (en) | 2013-03-14 | 2018-11-21 | Translate Bio, Inc. | Quantitative assessment for cap efficiency of messenger rna |
CN105051213A (zh) | 2013-03-14 | 2015-11-11 | 夏尔人类遗传性治疗公司 | 信使rna加帽效率的定量评估 |
EP3578663A1 (en) | 2013-03-15 | 2019-12-11 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
EP2971161B1 (en) | 2013-03-15 | 2018-12-26 | ModernaTX, Inc. | Ribonucleic acid purification |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014152030A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Removal of dna fragments in mrna production process |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
EP3971287A1 (en) | 2013-07-11 | 2022-03-23 | ModernaTX, Inc. | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
WO2015011633A1 (en) | 2013-07-23 | 2015-01-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for delivering messenger rna |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015034928A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
US20160264614A1 (en) | 2013-10-02 | 2016-09-15 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
CA2927393A1 (en) | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
EP3077406B1 (en) * | 2013-12-05 | 2019-07-10 | New England Biolabs, Inc. | Compositions and methods for capping rna |
WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
US20150167017A1 (en) | 2013-12-13 | 2015-06-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
PT3134131T (pt) | 2014-04-23 | 2022-03-24 | Modernatx Inc | Vacinas de ácidos nucleicos |
EP3201338B1 (en) | 2014-10-02 | 2021-11-03 | Arbutus Biopharma Corporation | Compositions and methods for silencing hepatitis b virus gene expression |
WO2016071857A1 (en) | 2014-11-07 | 2016-05-12 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus expression |
EP3218508A4 (en) | 2014-11-10 | 2018-04-18 | Modernatx, Inc. | Multiparametric nucleic acid optimization |
EP3041948B1 (en) | 2014-11-10 | 2019-01-09 | Modernatx, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
WO2016118724A1 (en) | 2015-01-21 | 2016-07-28 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
EP3247398A4 (en) | 2015-01-23 | 2018-09-26 | Moderna Therapeutics, Inc. | Lipid nanoparticle compositions |
WO2016154127A2 (en) | 2015-03-20 | 2016-09-29 | Protiva Biotherapeutics, Inc. | Compositions and methods for treating hypertriglyceridemia |
WO2016164762A1 (en) | 2015-04-08 | 2016-10-13 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same |
-
2016
- 2016-10-14 CA CA3001852A patent/CA3001852A1/en active Pending
- 2016-10-14 CN CN202210265648.6A patent/CN114686548A/zh active Pending
- 2016-10-14 WO PCT/US2016/057044 patent/WO2017066573A1/en active Application Filing
- 2016-10-14 US US15/294,249 patent/US10144942B2/en active Active
- 2016-10-14 ES ES16795177T patent/ES2862412T3/es active Active
- 2016-10-14 EP EP21151172.0A patent/EP3878955A1/en active Pending
- 2016-10-14 MA MA056219A patent/MA56219A/fr unknown
- 2016-10-14 CN CN201680060626.9A patent/CN108473969B/zh active Active
- 2016-10-14 AU AU2016338559A patent/AU2016338559B2/en active Active
- 2016-10-14 JP JP2018519481A patent/JP6997704B2/ja active Active
- 2016-10-14 EP EP16795177.1A patent/EP3362555B1/en active Active
-
2018
- 2018-10-19 US US16/165,372 patent/US10995354B2/en active Active
-
2021
- 2021-03-30 US US17/217,752 patent/US20220010347A1/en not_active Abandoned
- 2021-06-30 JP JP2021108662A patent/JP7119181B6/ja active Active
-
2023
- 2023-10-05 US US18/481,401 patent/US20240175065A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004532033A (ja) * | 2001-05-04 | 2004-10-21 | コーネル リサーチ ファンデイション インコーポレイテッド | 発現し難いタンパク質用の迅速に開裂可能なsumo融合タンパク質発現系 |
JP2010514451A (ja) * | 2006-12-29 | 2010-05-06 | ライフセンサーズ、インク. | タンパク質の発現増強および精製の方法および組成 |
WO2014028429A2 (en) * | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
Non-Patent Citations (1)
Title |
---|
KYRIELEIS O. J. P. ET AL.: "Crystal structure of vaccinia virus mRNA capping enzyme provides insights into the mechanism and evo", STRUCTURE, vol. 22, no. 3, JPN6020032264, 2014, pages 452 - 465, XP055329824, ISSN: 0004336313, DOI: 10.1016/j.str.2013.12.014 * |
Also Published As
Publication number | Publication date |
---|---|
JP7119181B2 (ja) | 2022-08-16 |
US20220010347A1 (en) | 2022-01-13 |
MA56219A (fr) | 2022-04-20 |
US20190136283A1 (en) | 2019-05-09 |
CN114686548A (zh) | 2022-07-01 |
JP2021155447A (ja) | 2021-10-07 |
JP7119181B6 (ja) | 2022-11-11 |
US10144942B2 (en) | 2018-12-04 |
US20170159093A1 (en) | 2017-06-08 |
ES2862412T3 (es) | 2021-10-07 |
CN108473969B (zh) | 2022-09-13 |
EP3362555A1 (en) | 2018-08-22 |
EP3362555B1 (en) | 2021-01-13 |
US20240175065A1 (en) | 2024-05-30 |
WO2017066573A1 (en) | 2017-04-20 |
CN108473969A (zh) | 2018-08-31 |
CA3001852A1 (en) | 2017-04-20 |
US10995354B2 (en) | 2021-05-04 |
AU2016338559B2 (en) | 2022-11-24 |
JP6997704B2 (ja) | 2022-02-04 |
AU2016338559A1 (en) | 2018-05-10 |
EP3878955A1 (en) | 2021-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7119181B2 (ja) | 生産性向上のためのrna関連酵素の修飾 | |
JP2018531017A6 (ja) | 生産性向上のためのrna関連酵素の修飾 | |
AU2016200460B2 (en) | Cells for producing recombinant iduronate-2-sulfatase | |
JP2015523074A (ja) | 組換えイズロン酸2スルファターゼの製造方法 | |
TR201802361T4 (tr) | Doğal olmayan amino asit replikasyonuna bağımlı mikroorganizmalar ve aşılar. | |
US8642291B2 (en) | Method for producing proteins comprising non-natural amino acids incorporated therein | |
US20200407731A1 (en) | Novel promoter and use thereof | |
Liu et al. | Selenophosphate Synthetase | |
EA044790B1 (ru) | Клетки для получения рекомбинантной идуронат-2-сульфатазы |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191011 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200821 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200831 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210630 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6997704 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |